Skip to content

The Causal Role of Ketone Bodies in Obesity-associated Disease Prevention - Combining Genetic Epidemiology With a Randomised Trial to Infer Causality

The Causal Role of Ketone Bodies in Obesity-Associated Disease Prevention - Combining Genetic Epidemiology With a Randomised Trial to Infer Causality

Status
Completed
Phases
Unknown
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT06668168
Acronym
KETO-GENETIC
Enrollment
69
Registered
2024-10-31
Start date
2025-05-06
Completion date
2026-06-03
Last updated
2026-06-15

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Nutrition, Obesity and Overweight

Keywords

Ketogenic diet

Brief summary

Excess weight increases the risk of several diseases including cardiovascular disease, type 2 diabetes, kidney disease and various cancers. There is a need for preventative strategies for obesity-associated disease, especially for people in the overweight and moderately obese ranges where pharmacological intervention may not be suitable. Low-carbohydrate (ketogenic) diets are popular for weight control. Ketogenic diets increase circulating ketones, which can have favourable effects on cardiometabolic health markers. However, the ketogenic diet has a nutrient composition associated with harms (high-saturated fat/red meat, and low-fibre). The net effects of ketogenic diets on long-term health are unclear. Ketone supplements can increase circulating ketones and could provide benefits of ketosis without needing to adhere to a potentially harmful diet. Establishing causality between complex exposures (e.g., diet) and long-term outcomes (e.g., disease), is challenging. The MRC & NIHR Review of Nutrition and Human Health Research (2017) highlighted an "overreliance (as opposed to reasonable reliance) on observational studies" as a key barrier to progression in the field of nutrition and health. Randomised controlled trials (RCTs) facilitate causal inference, but for long-term outcomes are expensive, time-consuming, and often suffer from waning adherence. Mendelian randomization (MR) can estimate causal effects subject to key assumptions. A challenge to these assumptions includes complex behavioural exposures (e.g., diet), which could be intercorrelated with causal factors. Our proposal will address these limitations with a novel combination of study designs to establish causal effects of ketosis (via diet and supplementation) on obesity-associated disease risk in humans. The investigators will combine a tightly controlled, short-term RCT, with MR to link short-term responses to long-term endpoints. The investigators will examine the circulating (blood) and tissue-specific (adipose) transcriptomic and proteomic responses in the fasted and postprandial state in response to our dietary interventions and translate these to MR by identifying single-nucleotide polymorphisms from genome wide association studies. This approach overcomes limitations of RCTs and MR, as adherence to diets will be confirmed with controlled feeding, and intermediate molecular traits as exposure for MR are less likely to be intercorrelated with causal traits.

Interventions

DIETARY_SUPPLEMENTKetone Monoester (KE)

25g ketone ester 3x/day. The ketone ester will be a beta-hydroxybutyrate monoester \[(R)-3-hydroxybutyl (R)-3-hydroxybutyrate\].

BEHAVIORALKetogenic diet

Ketogenic diet (\<50 g carbohydrate per day)

Sponsors

University of Bath
Lead SponsorOTHER
University of Bristol
CollaboratorOTHER
Imperial College London
CollaboratorOTHER

Study design

Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
BASIC_SCIENCE
Masking
NONE

Masking description

Outcome assessors will be masked to the group allocation when analysis is outsourced from the University.

Eligibility

Sex/Gender
ALL
Age
18 Years to 65 Years
Healthy volunteers
Yes

Inclusion criteria

* Body mass index: 25-45 kg/m2 * Waist circumference \>93.9 (males) or \>79.9 (females)

Exclusion criteria

* Glucose or lipid lowering medication * Diagnosis of cardiovascular disease, renal failure, liver disease or type 2 diabetes * Contraindications to a ketogenic diet (e.g., pancreatitis, liver failure, disorders of fat metabolism, primary carnitine deficiency, carnitine palmitoyltransferase deficiency, carnitine translocase deficiency, porphyrias, or pyruvate kinase deficiency) * Unable to understand English language

Design outcomes

Primary

MeasureTime frameDescription
Plasma proteomeFrom baseline to week 4Plasma proteome at week 4 adjusted for baseline values
Transcriptome of peripheral blood mononuclear cellsFrom baseline to week 4Transcriptome of peripheral blood mononuclear cells at week 4 adjusting for baseline values
Transcriptome of adipose tissueFrom baseline to week 4Transcriptome of subcutaneous abdominal adipose tissue at week 4 adjusting for baseline values

Secondary

MeasureTime frameDescription
Apolipoprotein B concentrationsFrom baseline to week 4Plasma apolipoprotein B concentrations at week 4 adjusted for baseline values.
Urinary albumin concentrationsFrom baseline to week 4Urinary albumin concentrations at week 4 adjusting for baseline values
Fasting glucose concentrationsFrom baseline to week 4Plasma fasting glucose concentrations at week 4 adjusting for baseline values

Countries

United Kingdom

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Jun 16, 2026